Jpmorgan Chase & CO Mei Pharma, Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.21 - $0.35 $1,084 - $1,807	-5,163 Reduced 86.12%	832 $0
Q4 2022 Feb 13, 2023	BUY	$0.22 - $8.4 $475 - $18,169	2,163 Added 56.45%	5,995 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.41 - $8.8 $67,014 - $1.44 Million	-163,450 Reduced 97.71%	3,832 $1,000
Q2 2022 Aug 11, 2022	BUY	$0.42 - $0.65 $43,461 - $67,262	103,480 Added 162.19%	167,282 $102,000
Q1 2022 May 11, 2022	SELL	$0.54 - $2.74 $25,113 - $127,426	-46,506 Reduced 42.16%	63,802 $39,000
Q4 2021 Feb 10, 2022	BUY	$2.33 - $3.37 $149,791 - $216,650	64,288 Added 139.7%	110,308 $294,000
Q3 2021 Nov 12, 2021	BUY	$2.52 - $2.99 $115,970 - $137,599	46,020 New	46,020 $127,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $385M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.